ATE262362T1 - Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung - Google Patents

Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung

Info

Publication number
ATE262362T1
ATE262362T1 AT00956565T AT00956565T ATE262362T1 AT E262362 T1 ATE262362 T1 AT E262362T1 AT 00956565 T AT00956565 T AT 00956565T AT 00956565 T AT00956565 T AT 00956565T AT E262362 T1 ATE262362 T1 AT E262362T1
Authority
AT
Austria
Prior art keywords
cyamemazine
withdrawing
symptoms
treat
benzodiazepine treatment
Prior art date
Application number
AT00956565T
Other languages
English (en)
Inventor
Alche-Biree Francoise D
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE262362T1 publication Critical patent/ATE262362T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00956565T 1999-08-13 2000-07-28 Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung ATE262362T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9910472A FR2797399B1 (fr) 1999-08-13 1999-08-13 Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
PCT/FR2000/002186 WO2001012265A1 (fr) 1999-08-13 2000-07-28 Utilisation de la cyamemazine dans le traitement du sevrage brutal aux benzodiazepines

Publications (1)

Publication Number Publication Date
ATE262362T1 true ATE262362T1 (de) 2004-04-15

Family

ID=9549128

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00956565T ATE262362T1 (de) 1999-08-13 2000-07-28 Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung

Country Status (12)

Country Link
US (1) US6534500B2 (de)
EP (1) EP1212119B1 (de)
JP (1) JP5078209B2 (de)
AT (1) ATE262362T1 (de)
AU (1) AU6846300A (de)
CA (1) CA2381354C (de)
DE (1) DE60009315T2 (de)
DK (1) DK1212119T3 (de)
ES (1) ES2214305T3 (de)
FR (1) FR2797399B1 (de)
PT (1) PT1212119E (de)
WO (1) WO2001012265A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850871B1 (fr) 2003-02-07 2006-07-14 Aventis Pharma Sa Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament
CA2513920A1 (en) * 2003-02-07 2004-08-26 Aventis Pharmaceuticals Inc. Application of 2-cyano-10- (2-methyl-3-(methylamino)- propyl)phenothiazine or a pharmaceutically acceptable salt as medicament
US7855196B2 (en) * 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
DE102011078999A1 (de) 2011-07-12 2013-01-17 Carl Zeiss Sms Gmbh Verfahren und Vorrichtung zur Positionsbestimmung von Strukturen auf einer Maske für die Mikrolithographie
DE102013101445B9 (de) 2013-02-14 2022-01-05 Carl Zeiss Smt Gmbh Verfahren zur Ermittlung von Verzeichnungseigenschaften eines optischen Systems in einer Messvorrichtung für die Mikrolithographie
DE102013106320B9 (de) 2013-06-18 2021-07-01 Carl Zeiss Smt Gmbh Verfahren zur Ermittlung von Verzeichnungseigenschaften eines optischen Systems in einer Messvorrichtung für die Mikrolithographie
DE102013107976B4 (de) 2013-07-25 2016-07-28 Carl Zeiss Sms Gmbh Positionsbestimmung von Strukturen auf einer Maske für die Mikrolithographie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE552557A (de) * 1955-11-15
US4666903A (en) * 1985-08-13 1987-05-19 Yale University Novel use of benzodiazepine antagonist
FR2654621B1 (fr) * 1989-11-22 1994-09-23 Esteve Labor Dr Inhibition du syndrome d'abstinence.
JPH06508836A (ja) * 1991-06-26 1994-10-06 セプラコア,インコーポレーテッド 光学的に純粋なr(+)オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
AU727781B2 (en) 1997-04-02 2000-12-21 Bioniche Life Sciences Inc. Use of bacterial cell wall extract for preventing, treating, or eliminating a protozoal or parasitic disease

Also Published As

Publication number Publication date
DE60009315T2 (de) 2005-02-17
EP1212119B1 (de) 2004-03-24
JP5078209B2 (ja) 2012-11-21
AU6846300A (en) 2001-03-13
ES2214305T3 (es) 2004-09-16
JP2003507352A (ja) 2003-02-25
FR2797399A1 (fr) 2001-02-16
PT1212119E (pt) 2004-07-30
US6534500B2 (en) 2003-03-18
DK1212119T3 (da) 2004-06-21
WO2001012265A1 (fr) 2001-02-22
EP1212119A1 (de) 2002-06-12
DE60009315D1 (de) 2004-05-13
CA2381354A1 (fr) 2001-02-22
CA2381354C (en) 2008-12-30
US20020183332A1 (en) 2002-12-05
FR2797399B1 (fr) 2002-10-18

Similar Documents

Publication Publication Date Title
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
BR0011130A (pt) Inibidores de metaloproteases
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
SE9902267D0 (sv) New compounds
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
UY26426A1 (es) Nuevos compuestos
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
NO990450L (no) Behandling av sinnslidelser
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ATE278401T1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE50010972D1 (de) UBICHINON Qn ZUR BEHANDLUNG VON MIGRÄNESCHMERZEN

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1212119

Country of ref document: EP